Federal health officials’ recommendation against routine PSA testing is putting men at risk, a leading prostate cancer doctor warns.

David B. Samadi, M.D., a board-certified urologic oncologist trained and expert in robotic prostate surgery, argues the 2011 U.S. Preventive Services Task Force (USPSTF) guideline against prostate specific antigen for most men leaves many at risk of developing aggressive cases of cancer.

The task force concluded that the PSA test has no benefit or that the harms outweigh the benefits.

But Dr. Samadi tells Fox News the recommendation fails to consider the tremendous benefits early screening can offer men at risk.

“Instead of focusing on the benefits of PSA screening and how much it has actually helped the health care system, their recommendations focus on the complications of treatment, such as incontinence and erectile dysfunction,” said Dr. Samadi, chairman of urology, chief of robotic surgery at Lenox Hill Hospital and professor of urology at Hofstra North Shore-LIJ School of Medicine. “However, these complications depend on how experienced the surgeon is that you are being treated by.”

He adds that prostate cancer mortality was on the decline before the USPSTF issued its recommendation. Since incorporating the PSA test, there has been a 40 percent reduction in prostate cancer mortality in the United States.

He argues that PSA screening can help detect prostate cancer early, make cases easier to treat, and is easily done with a simple blood test.

“Screening doesn’t lower your risk of having prostate cancer; it increases the chance you’ll find out you have it,” he noted.